tbuckley/cabot-search huggingface dataset:
Appending Thrombus on Ulceration of the Ascending Aorta
Authors: Olivier F. Bertrand, Sylvain Trahan, Josep Rodés-Cabau, Éric Dumont
Journal: Circulation (2009)

A 61-year-old man presented to the emergency depart- ment with typical acute chest pain of Ͻ4 hours duration.ECG showed 2-mm ST-segment elevations in inferior leads, and the cardiac catheterization team was called for primary percutaneous coronary intervention.Angiography of the right dominant coronary artery did not show significant lesion but distal embolization and slow flow (Figure 1).Angiography of the left coronary artery showed a moderate lesion in the left anterior descending artery with a normal circumflex artery.Right anterior oblique ventriculography showed a severe posterobasal hypokinesia compatible with an acute inferior myocardial infarction.Left anterior oblique ventriculography showed moderate-severe inferior hypokinesia, and unexpectedly a large moving filling defect was visible in the ascending aorta just above the right coronary ostium (Figure 2 and online-only Data Supplement Movie).Urgent operation was carried out, and a segment of the aorta with the appending mass (Figure 3) was removed and replaced by a Dacron prosthesis.Microscopic examination showed an ulcerated intimal atheromatous plaque with adherent acute fibrinous thrombus (Figure 4A).Admixed leukocytes were present within the thrombus, but no granulation tissue or hemosiderin pigment was seen (Figure 4B).Staining for microorganisms was negative.No medial cystic degeneration or sign of aortitis was found.The patient made an uneventful recovery.In acute coronary syndrome, coronary embolization is sometimes suspected when no significant coronary stenosis can be found in the culprit artery.Our case illustrates that, in rare cases, myocardial infarction can be caused by embolization of thrombotic material originating from aortic ulceration.
An inducible long noncoding RNA amplifies DNA damage signaling
Authors: Adam M Schmitt, Julia T Garcia, Tiffany Hung, Ryan A Flynn, Ying Shen, Kun Qu, Alexander Y Payumo, Ashwin Peres-da-Silva, Daniela Kenzelmann Broz, Rachel Baum, Shuling Guo, James K Chen, Laura D Attardi, Howard Y Chang
Journal: Nature Genetics (2016)
Capecitabine (XEL) and Mitomycin-C (MMC) used concurrently with accelerated concomitant boost radiation therapy (CB-RT) in head and neck cancer (SCCHN): Preliminary results of a phase I clinical trial
Authors: B. G. Haffty, A. Psyrri, J. K. Joe, D. Slater, W. Zaheer, L. D. Wilson, Y. Son, C. Sasaki, E. Chu
Journal: Journal of Clinical Oncology (2005)

5595 Background: To determine the dose limiting toxicity (DLT) of XEL when used in combination with MMC and CB-RT in the management of SCCHN. Methods: Previously untreated locally advanced Stage III/IV SCHHN referred for primary chemo-radiation were eligible for this prospective trial. Prophylactic feeding tubes were encouraged and radioprotectors were not allowed. Following IRB approved informed consent, 15 patients entered the trial between 3/03 and 7/04. CB-RT was delivered as per RTOG 9003 to a total dose of 72 Gy in 6 weeks. MMC was administered intravenously on the first and last day of RT at a fixed dose of 15mg/M2. The planned XEL dose escalation schedule in groups 3–4 patients was: 500, 625, 825, 900, 1000, and 1250 mg/M2 given orally twice daily throughout RT (Mon-Fri). Results: As of November 2004,15 patients have entered the trial. The most recent cohort completed treatment at a XEL level of 900mg/M2. The majority of patients have experienced G3 mucositis and epidermitis, and have required either G-Tube feeding or supplemental IV hydration. One patient expired prior to completion of therapy (non-treatment related) with normal blood counts and a near complete resolution of measurable disease. All others have completed the prescribed course of therapy without RT delays. G3–4 toxicities have been as expected and acceptable. Of 14 patients completing the protocol, 12 (86%) achieved a complete clinical and/or radiographic response. Of the two incomplete responses, one patient achieved a near CR, and subsequently progressed, the second is awaiting a PET scan and re-evaluation. The remaining patients remain locally controlled with a relatively short median follow-up of 12 months. Conclusions: This aggressive concurrent chemo-radiation regimen of MMC, XEL and CB-RT, at the current XEL dose of 900 mg/M2, appears to be well tolerated and DLT has not been reached. We continue to dose escalate XEL, and updated results of the trial will be presented. Response rates and local control appear to be promising, but longer follow-up is needed. Once the DLT of XEL is defined, this regimen should be tested in a controlled randomized trial. No significant financial relationships to disclose.
Correction to “International Union of Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors”
Journal: Pharmacological Reviews (2014)

In the above article [Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AEI, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, and Zlotnik A (
P0133 : Nutrition and physical therapy targets are not being met in admitted patients with cirrhosis
Authors: R. Pai, T. Shaikh, M. Ma, J. Gonzalez-Abraldes, R. Ameen, A. Shah, S. Robbins, K. Qumosani, B. Aljudaibi, A. Rahman, P. Tandon
Journal: Journal of Hepatology (2015)
TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG).
Authors: Trevor Leong, Mark Smithers, Michael Michael, Val Gebski, Alex Boussioutas, Danielle Miller, John Raymond Zalcberg, Rebecca Wong, Karin Haustermans
Journal: Journal of Clinical Oncology (2012)

TPS4141 Background: Optimal management of patients with resectable gastric cancer remains unknown. Since the INT0116 and MAGIC trials, there are 2 standards of care for adjuvant therapy: postoperative chemoradiotherapy (CRT) and perioperative ECF chemotherapy. The important question arising from these studies is whether CRT is superior to chemotherapy alone as adjuvant therapy. This randomized phase II/III trial will compare CRT to chemotherapy alone in the preoperative setting. Methods: Patients with resectable adenocarcinoma of the stomach or gastroesophageal junction will be randomized to receive either preoperative chemotherapy alone (ECFx3 as per MAGIC regimen) or preoperative CRT (ECFx2 followed by 45Gy of radiation with concurrent 5-FU). Following surgery, both groups will receive 3 further cycles of ECF. The trial is being conducted in two Parts; Part I (phase II component) will recruit 120 patients with the aim of demonstrating sufficient efficacy and safety of preoperative CRT, as well as trial feasibility. Part II (phase III component) will recruit a further 632 patients to provide a total of 752. The primary endpoint for Part I is pathological complete response rate, and for Part 2 it is overall survival. The trial includes formal quality of life and biological sub-studies. In addition, the trial incorporates a rigorous quality assurance program that includes real time central review of radiotherapy plans and central review of surgical technique. Current status: This study is an international, intergroup trial led by the Australasian Gastro-Intestinal Trials Group (AGITG), in collaboration with the Trans-Tasman Radiation Oncology Group (TROG), European Organisation for Research and Treatment of Cancer (EORTC) and the NCIC Clinical Trials Group. To date, 36 patients have been recruited from 20 sites in Australia and New Zealand; European and Canadian sites will commence recruitment in 2012.
Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma.
Authors: Johannes Drach, Verena Sagaster, Victoria Odelga, Hannes Kaufmann, Jutta Ackermann, Markus Galhuber, Niklas Zojer, Elisabeth Küenburg, Christoph Zielinski, Rotraud Wieser, Heinz Ludwig
Journal: Blood (2006)
Rearrangements of 12p in Acute Myeloid Leukemia (AML) Remain a Significant Adverse Prognostic Marker When Patients Are Treated with Stem Cell Transplantation
Authors: Claudia Ulrike Walter, Fahed Almhareb, Naeem A. Chaudhri, Hazzaa Al Zahrani, Wahiba Chebbo, Khalid Ibrahim, Mohammad Bakr, Said Mohamed, Walid Rasheed, Fahad Alsharif, Mahmoud Aljurf, Maher Albitar
Journal: Blood (2011)
Implications of the Definition of an Episode of Care Used in the Comprehensive Care for Joint Replacement Model
Authors: Chad Ellimoottil, Andrew M. Ryan, Hechuan Hou, James M. Dupree, Brian Hallstrom, David C. Miller
Journal: JAMA Surgery (2016)

Under the Comprehensive Care for Joint Replacement (CJR) model, hospitals are held accountable for nearly all Medicare payments that occur during the initial hospitalization until 90 days after hospital discharge (ie, the episode of care). It is not known whether unrelated expenditures resulting from this "broad" definition of an episode of care will affect participating hospitals' average episode-of-care payments.To compare the CJR program's broad definition of an episode of care with a clinically narrow definition of an episode of care.We identified Medicare claims for 23 251 patients in Michigan who were Medicare beneficiaries and who underwent joint replacement during the period from 2011 through 2013 at hospitals located in metropolitan statistical areas. Using specifications from the CJR model and the clinically narrow Hospital Compare payment measure, we constructed episodes of care and calculated 90-day episode payments. We then compared hospitals' average 90-day episode payments using the 2 definitions of an episode of care and fit linear regression models to understand whether payment differences were associated with specific hospital characteristics (average Centers for Medicare & Medicaid Services-hierarchical condition categories risk score, rural hospital status, joint replacement volume, percentage of Medicaid discharges, teaching hospital status, number of beds, percentage of joint replacements performed on African American patients, and median income of the hospital's county). We performed analyses from July 1 through October 1, 2015.The correlation and difference between average 90-day episode payments using the broad definition of an episode of care in the CJR model and the clinically narrow Hospital Compare definition of an episode of care.We identified 23 251 joint replacements (ie, episodes of care). The 90-day episode payments using the broad definition of the CJR model ranged from $17 349 to $29 465 (mean [SD] payment, $22 122 [$2600]). Episode payments were slightly lower (mean payment, $21 670) when the Hospital Compare definition was used. Both methods were strongly correlated (r = 0.99, P < .001). The average payment difference between these 2 types of episodes of care was small (mean [SD], $452 [$177]; range, $73-$1006). In our multivariable analysis, we found that the hospital characteristics examined had a minimal impact or no impact on the payment differential.The average 90-day episode payments determined by both definitions of an episode of care were strongly correlated, and there was a small payment differential for most hospitals. In the context of joint replacement bundled payments, these data suggest that hospital performance will be consistent whether a broad or clinically narrow definition of an episode of care is used.
Gemcitabine and nab-paclitaxel in patients with unresectable/borderline resectable pancreatic cancer.
Authors: P. Thapaliya, M. N. Kundranda, K. K. Curtis, M. D. Callister, J. B. Ashman, J. Collins, A. Moss, K. L. Mekeel, A. C. Silva, M. J. Borad
Journal: Journal of Clinical Oncology (2010)

e14675 Background: Targeting the tumor stroma has evolved as a promising therapeutic strategy. Secreted protein acidic rich in cysteine (SPARC) which binds albumin has been putatively linked to enhanced drug delivery of nab-paclitaxel (ABX) to pancreatic tumor stroma. A recent phase I/II study demonstrated a 44% response in patients with metastatic pancreatic cancer treated with gemcitabine (gem) and ABX (Von Hoff et al, ASCO 2009). Based on these encouraging results, a pilot investigation was conducted in patients with unresectable (UR)/borderline resectable (BR) disease. Methods: A retrospective review was done on UR/BR pancreatic ca patients treated at Mayo Clinic Arizona from 3/09-12/09. Patients received gemcitabine 1,000 mg/m2 and nab-paclitaxel 100-125 mg/m2 neoadjuvantly. Demographics, staging, RECIST response, CA19-9 response (defined as > 50% maximal decline), EORTC PET response, post-treatment resectabilty and treatment related toxicities were assessed. Results: 13 patients were treated with this combination (age: median 69, range 47-86 years; sex: male 6, female 7, ECOG: 0-10, 1-3; location: head 8, body 5, median baseline CA19-9: 397 u/mL). A median of 3 cycles of therapy was delivered (range: 3-6). 3/13 (23%) underwent surgical resection with curative intent. CA19-9 response was 13/13 (100%), RECIST response was: PR-9/13 (69%), SD-3/13 (23%) and PD-1/13 (8%). EORTC PET response was: PR-7/10 (70%), SD3/10 (30%). No patients encountered drug related grade 4 or higher toxicities. There were 2 cases of grade 3 neutropenia,1 case of grade 3 anemia and no cases of grade 3 or higher thrombocytopenia; 4 patients had grade 2 neuropathy. Conclusions: Gemcitabine and nab-paclitaxel has a very promising antitumor activity in unresectable and borderline resectable pancreatic cancer patients. Investigation in a larger cohort of patients is ongoing. No significant financial relationships to disclose.
Treatment of the elderly with high-grade bone and soft-tissue sarcomas (BSTS)
Authors: H. Tsuchiya, S. Ii, N. Yamamoto, M. Karita, T. Shirai, H. Nishida, M. Hayashi, K. Tomita
Journal: Journal of Clinical Oncology (2004)

9055 Background: For patients with high-grade BSTS who are over 60 years of age, we expect to obtain similar benefits from neoadjuvant chemotherapy (C) and surgical treatment as we do with their younger counterparts. In this study, we reviewed clinical outcomes of treatment for these patients. Methods: We treated 55 elderly patients with high-grade BSTS between 1989 and 2000. The mean age was 69 years. We performed preoperative caffeine-potentiated C consisting of cisplatin, doxorubicin, and caffeine for 32 patients. C regimens were: i.a. cisplatin 120 mg/m2 for 1 day, i.a. doxorubicin 30 mg/m2 for 2 days, i.a. caffeine 1500 mg/m2 for 3 days, 3 to 5 cycles at 3-week intervals. The dosage of cisplatin and doxorubicin was reduced by 10 to 30% according to creatinine clearance and performance status. Surgery was performed for 51 patients. Results: Of 32 patients who were treated with preoperative C, 23 patients (72%) received more than 3 courses, but 9 (28%) were stopped within 2 courses. Of those patients receiving more than 3 courses of C good responders (clinically confirmed PR or CR, or histologically identified more than 90% of necrosis) were 5 of 7 (71%) with bone sarcomas and 8 of 16 (50%) with soft-tissue sarcomas. The 5-year disease-free survival rate (SR) was 41% in stage II patients treated with surgery combined with more than 3 courses of C and 33% in those treated with surgery alone or combined with less than 2 courses of C. The 5-year overall SR of good responders for more than 3 courses of C was 80%, and of poor responders (clinically confirmed NC, or histologically identified less than 90% of necrosis) was 47%. The 5-year local recurrence-free SR of stage II patients treated with adequate wide surgical margins was 75%, and with inadequate margins was 39% (p<0.01), and the 5-year overall SR was 78% and 66%, respectively. Conclusions: Good C responders who received more than 3 courses showed the best survival rate. However, we could not find statistically significant differences in SR between sufficient C and insufficient or no C group. For all patients, especially poor responders, an adequate surgical margin was the most necessary for a favorable outcome. No significant financial relationships to disclose.
Patterns of Lymphocytosis in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Idelalisib
Authors: Jennifer R. Brown, Bruce D. Cheson, Richard R. Furman, Paolo Ghia, Michael Hallek, Peter Hillmen, Susan M. O'Brien, Jeff P. Sharman, Ronald L. Dubowy, Barbara Velasco, Christopher C. Waldapfel, Andrew D. Zelenetz
Journal: Blood (2015)
Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).
Authors: Jonathan E. Rosenberg, Elisabeth I. Heath, Peter J. Van Veldhuizen, Jaime R. Merchan, Joshua Michael Lang, Joseph D. Ruether, Daniel Peter Petrylak, Randeep S. Sangha, David C. Smith, Srikala S. Sridhar, Elaina M. Gartner, Martha Vincent, Rong Chu, Banmeet Anand, Fernando Donate, Lynnae Jackson, Leonard M. Reyno, Jingsong Zhang
Journal: Journal of Clinical Oncology (2016)

4533 Background: Nectin-4 is a cell adhesion molecule expressed on several tumor types, including mUC. ASG-22ME is an antibody drug conjugate (ADC) that delivers a small molecule microtubule-disrupting agent, monomethyl auristatin E (MMAE), to tumor cells expressing Nectin-4. Methods: Pts with solid tumors including mUC treated with ≥ 1 prior chemo regimen or mUC pts unfit for Cisplatin were enrolled using a modified continual reassessment method design. Pts were prescreened for Nectin-4 expression (IHC assay) and enrolled if H-score ≥150. Disease assessments (DA) were performed every 8 weeks (wks) using RECIST v 1.1. ASG-22ME was administered IV wkly for 3 out of every 4 wks until no further clinical benefit. 4 dose levels were studied: .5, .75, 1, or 1.25 mg/kg. Results: Of analyzed tumor tissues, 93% (n=243) were Nectin-4 positive (83% had H-score ≥ 150). As of 1/21/16, 39 solid tumor pts were enrolled; 31 with mUC reported here. Median age= 65 y; 100% ECOG PS ≤ 1; 21 pts (68%) had ≥ 2 lines of prior therapy for mUC. 7 pts (25%) had a PR (ORR (PR and CR) =25%), including 3/10 pts (30%) with liver metastasis. Median time on study was 15 wks. 30 pts (97%) had adverse events (AEs). The most common AE was fatigue (42%). 18 pts (58%) had Grade 3/4 AEs, with 44% considered related. 7 pts (23%) had eye disorders (Grade 1/2). 2 pts (6%) had protocol defined dose limiting toxicities. There were 2 deaths unrelated to study drug. Serum concentration of ASG-22ME decreased multi-exponentially and exposure was dose-proportional. ASG-22ME half-life is 1.5 days. Anti-tumor activity was seen at all dose levels. The median progression free survival is 17 wks (unplanned exploratory analysis). Enrollment is open at active dose levels: updated results will be presented. Conclusions: ASG-22ME targeting Nectin-4 is an ADC in mUC that is well tolerated and active. These results warrant ongoing study of ASG-22ME in mUC pts. Clinical trial information: NCT02091999.mUC Pts only. Dose (mg/kg) 0.5 0.75 1 1.25 Evaluable pts (n=28) 2 11 11 4 ORR, n (%) 1 (50) 3 (27) 1 (9) 2 (50) Responders (PR/CR) Median Duration on Rx (Wks) 65 24 31 12 DCR (SD/PR/CR) n (%) 2 (100) 9 (82) 7 (64) 3 (75) Evaluable pts = ≥ 1 dose of drug and ≥ 1 post-baseline DA.
A phase II trial of the proteosome inhibitor PS-341 in patients with metastatic colorectal cancer
Authors: H. Mackay, P. Major, C. Townsley, M. Mackenzie, M. Vincent, P. Degendorfer, M. Tsao, D. Hedley, J. Wright, A. Oza
Journal: Journal of Clinical Oncology (2004)

3109 Background: The ubiquitinin-proteosome proteolytic pathway regulates the metabolism of critical proteins involved in the cell cycle, apoptosis and metastasis such as p53, p21, p27 and NFκB. PS341(Bortezomib; Velcade) is a specific and selective inhibitor of the 26S proteosome. PS341 results in significant regression in a human colon cancer xenograft model. Methods: This phase II study aimed to assess the activity of PS341 in patients with metastatic colorectal cancer who had received no more than 1 prior line of chemotherapy with irinotecan (or oxaliplatin)/5 fluorouracil for metastatic disease. Primary endpoints were objective response or disease stabilization; with a multinomial stopping rule and secondary endpoints included assessment of molecular changes with therapy, survival and tolerability. PS 341 at a dose of 1.3mg/m2/day was administered as an intravenous bolus days 1,4,8 and 11 of a 21 day cycle. Tumor response was assessed by RECIST criteria every 2 cycles. Tumor biopsies were performed prior to treatment and on day 9 of the first treatment cycle. Results: 19 patients (9M:10F), median age 62 (range 46–81) years received 41 (range 1–4) cycles of treatment. 3 patients had stable disease (SD), 14 had progressive disease (PD) and 2 were non- evaluable . Of the 2 patients with SD at cycle 2, two patients discontinued treatment during cycle 4 due to grade 3 abdominal pain and grade 3 peripheral neuropathy. One patient had SD after 3 cycles but was withdrawn due to a cerebrovascular accident (CVA). The most common adverse events (AEs), any grade, were lymphopenia (80% of cycles), fatigue (77%), anemia (66%), constipation (61%), nausea(51%) and headache (42%). Discontinuation of treatment occurred due to the following AEs: grade 3 peripheral neuropathy (2 patients), CVA and grade 3 abdominal pain, myalgia and rash. Paired tumor biopsies were obtained from 9 patients and examined for transcription factors NFkβ and HIF-1α, p53, p27, and p21 by immunohistochemistry. Data will be presented at the meeting. Conclusions: PS341 has insufficient activity in colorectal cancer and the study has closed to accrual. No significant financial relationships to disclose.
Quantifying myocardial deformation throughout the cardiac cycle - A comparison of ultrasound strain rate, grey-scale M-mode and magnetic resonance imaging
Authors: Lieven Herbots, Frederik Maes, Jan D'hooge, Piet Claus, Steven Dymarkowski, P Mertens, Alex Maes, Jan Bogaert, Bart Bijnens, Frank Rademakers, GR Sutherland
Journal: Circulation (2003)